Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 4
1(50.0%)
2Total
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04303390Phase 4Completed

24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis

Role: lead

NCT04427046Completed

Acute Myocardial Infarction in Native Versus Non-native Young Population in Saudi Arabia

Role: lead

NCT05208424Completed

New Diabetes Mellitus and Pre-Diabetes With First-time Diagnosed Coronary Artery Disease

Role: lead

NCT05210972Completed

Coronary Artery Disease Severity in Newly Diagnosed Dysglycemia

Role: lead

NCT05208398Phase 3Completed

Apixaban in Patients With Left Ventricular Thrombus

Role: lead

NCT04572061Completed

Emergency Coronary Artery Bypass Graft in Acute Myocardial Infarction

Role: lead

All 6 trials loaded